

RNA interference - Pipeline Insight, 2022

<https://marketpublishers.com/r/R51E0B31F49FEN.html>

Date: January 2022

Pages: 70

Price: US\$ 2,000.00 (Single User License)

ID: R51E0B31F49FEN

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "RNA interference - Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in RNA interference pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

RNA interference Understanding

RNA interference: Overview

RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes. This natural mechanism for sequence-specific gene silencing promises to revolutionize experimental biology and may have important practical applications in functional genomics, therapeutic intervention, agriculture and other areas.

Function - RNA molecules play numerous roles in both normal cellular processes and

disease states. Generally, those RNA molecules that do not take the form of mRNA are referred to as noncoding, because they do not encode proteins. The involvement of noncoding mRNAs in many regulatory processes, their abundance, and their diversity of functions has led to the hypothesis that an 'RNA world' may have preceded the evolution of DNA and proteins e-specific RNA degradation process (posttranscriptional gene silencing [PTGS]/RNA interference [RNAi]). RNA silencing is a novel gene regulatory mechanism that limits the transcript level by either suppressing transcription (transcriptional gene silencing [TGS]) or by activating a sequenc

RNA interference - RNA interference (RNAi) is a biological process by which double-stranded RNA (dsRNA) induces sequence-specific gene silencing by targeting mRNA for degradation. As a tool for knocking down the expression of individual genes post transcriptionally, RNAi has been widely used to study the cellular function of genes.

RNA interference Emerging Drugs Chapters

This segment of the RNA interference report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

RNA interference Emerging Drugs

Fitusiran: Alnylam Pharmaceuticals

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by our collaborators at Sanofi Genzyme. The drug is currently in phase 3 of development for the treatment of patients with Haemophilia.

WVE 120102: WaVe life Sciences

WVE 120102 is being developed by WaVe life Sciences for the treatment of Huntington disease. The therapy is based on RNAi technology and targets a specific single nucleotide polymorphism (SNP3) within the huntingtin gene. It is currently in phase I/II of clinical development.

Further product details are provided in the report.....

RNA interference: Therapeutic Assessment

This segment of the report provides insights about the different RNA interference drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on RNA interference

There are approx. 20+ key companies which are developing the RNA interference. The companies which have their RNA interference drug candidates in the most advanced stage, i.e. phase 3 include, Alnylam Pharmaceuticals.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

RNA interference pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

RNA interference: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RNA interference therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RNA interference drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence RNA interference R&D. The therapies under development are focused on novel approaches for RNA interference.

RNA interference Report Insights

RNA interference Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

RNA interference Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing RNA interference drugs?

How many RNA interference drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for RNA interference?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the RNA interference therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for RNA interference and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Alnylam Pharmaceuticals

WaVe life Sciences

Medesis Pharma

Bio-Path Holdings

Sirnaomics

Arrowhead Pharmaceuticals

Silence Therapeutics

Dicerna Pharmaceuticals

Novo Nordisk

Eli Lilly and Company

Ionis Pharmaceuticals

Quark Pharmaceuticals

ProQR Therapeutics

Arbutus Biopharma

Atugen AG

Sylentis

Bristol-Myers Squibb

OliX Pharmaceuticals

Janssen Pharmaceuticals

Amgen

miRagen Therapeutics

Regulus Therapeutics

Key Products

Fitusiran

WVE 120102

siRNA therapeutic

BP 1003

STP 705

Research programme: short interfering RNA-based therapeutics

IONIS AGT LRx

QPI 1007

Teprasiran

Eluforsen

RG 6346

AB 729

QR-421a

Sepofarsen

PF 4523655

ALN VSP

Atu027

Bamosiran

BMS 986263

ARO APOC3

Tivanisiran

OLX 101A

TAK 999

Nedosiran

Olpasiran

Remlarsen

MRG 110

Lademirsen

Contents

Introduction

Executive Summary

RNA interference: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

RNA interference – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

RNA interference companies' collaborations, Licensing, Acquisition -Deal Value

Trends

RNA interference Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Fitusiran: Alnylam Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

IONIS AGT LRx : Ionis Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

QR-421a: ProQR Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

BP 1003: Bio-Path Holdings

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

RNA interference Key Companies**RNA interference Key Products****RNA interference- Unmet Needs****RNA interference- Market Drivers and Barriers****RNA interference- Future Perspectives and Conclusion****RNA interference Analyst Views****RNA interference Key Companies****Appendix**

List Of Tables

LIST OF TABLES

Table 1 Total Products for RNA interference

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for RNA interference

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: RNA interference - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/R51E0B31F49FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R51E0B31F49FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970